This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Ask the Experts: Optimizing the Use and Management of Immune Checkpoint Inhibitors

Ask the Experts: Optimizing the Use and Management of Immune Checkpoint Inhibitors


Slide Lecture Series

Time to Complete

1 hour


May 22, 2019


May 22, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Pharmacy Credits

Pharmacists may earn 1.00 CPE Credit (0.10 CEU) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck.

Program Description

Immune checkpoint inhibition continues to evolve as standard therapy for a growing number of solid and hematologic malignancies. This educational activity will explore the growing role of immune checkpoint inhibition as standard management for less common malignancies and new updated indications. Additionally, though the number of cancer indications continues to grow, immune checkpoint inhibition remains clinically beneficial for only select patients, depending on the diagnosis. The current literature centered on identifying clinically relevant predictive biomarkers will also be reviewed.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners who are interested in immune checkpoint inhibitors and their role in cancer treatment.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Discuss the current immune checkpoint inhibitors with a focus on novel agents and recent approvals.
  • Evaluate the literature supporting potential predictive biomarkers associated with clinical response to immune checkpoint inhibition in patients with solid tumors.
  • Examine the place in therapy of companion diagnostic testing for recommendation of immune checkpoint inhibitors.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships. In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.


Christine M. Walko, PharmD, BCOP, FCCP
Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Associate Professor
University of South Florida Morsani College of Medicine
Tampa, Florida

Dr. Walko discloses the following:
Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board

Ragini R. Kudchadkar, MD
Associate Professor
Winship Cancer Institute of Emory University
Associate Director Hematology/Oncology Fellowship Program
Atlanta, Georgia

Dr. Kudchadkar, MD
Array, Immunocore, Bristol-Myers Squibb: Advisory Board member
Merck: Research funding received

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the posttest. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue